DISCOUNT-ZERTIFIKAT - ASTRAZENECA Stock

Certificat

DE000SU229D4

Market Closed - Boerse Frankfurt Warrants 03:50:43 2024-05-28 pm EDT
88.75 EUR -0.03% Intraday chart for DISCOUNT-ZERTIFIKAT - ASTRAZENECA
Current month+0.32%
1 month+0.46%
Date Price Change
24-05-28 88.75 -0.03%
24-05-27 88.78 +0.02%
24-05-24 88.76 +0.01%
24-05-23 88.75 +0.08%
24-05-22 88.68 -0.05%

Real-time Boerse Frankfurt Warrants

Last update May 28, 2024 at 03:50 pm EDT

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying ASTRAZENECA PLC
IssuerLogo Issuer Société Générale Société Générale
WKN SU229D
ISINDE000SU229D4
Date issued 2023-12-01
Cap 9,000 p
Last trading day 2024-09-19
Maturity 2024-09-20 (115 Days)
Parity 1 : 1
Emission price 84.59
Emission volume N/A
Payment day 2024-09-27
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 0.000000 %
Sideways yield 0.000000 %
Sideways yield pa 0.000000 %
Outperformance point- p
Break even 0.000000 €
Highest since issue 88.81
Lowest since issue 84.63
Spread 0.11
Spread %0.12%
Distance Cap 3,028 p
Distance Cap %+25.17%
Max. earning-
Max. earning % 0.000000 %

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
More about the company

Ratings for AstraZeneca PLC

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: AstraZeneca PLC

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7 USD
Average target price
170.1 USD
Spread / Average Target
+10.69%
Consensus